15,502 Shares in BeOne Medicines Ltd. – Sponsored ADR $ONC Acquired by Greenwoods Asset Management Hong Kong Ltd.

Greenwoods Asset Management Hong Kong Ltd. purchased a new position in shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) during the second quarter, HoldingsChannel.com reports. The fund purchased 15,502 shares of the company’s stock, valued at approximately $3,753,000. BeOne Medicines accounts for 0.1% of Greenwoods Asset Management Hong Kong Ltd.’s portfolio, making the stock its 24th largest holding.

Other institutional investors also recently made changes to their positions in the company. Slow Capital Inc. purchased a new position in shares of BeOne Medicines in the 2nd quarter worth $4,377,000. Public Employees Retirement System of Ohio acquired a new stake in BeOne Medicines during the second quarter worth about $3,491,000. Sequoia Financial Advisors LLC purchased a new position in shares of BeOne Medicines in the 2nd quarter worth about $298,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of BeOne Medicines in the 2nd quarter worth about $926,000. Finally, Aaron Wealth Advisors LLC acquired a new position in shares of BeOne Medicines in the 2nd quarter valued at about $200,000. 48.55% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other BeOne Medicines news, SVP Chan Henry Lee sold 10,671 shares of the stock in a transaction on Wednesday, October 8th. The shares were sold at an average price of $350.40, for a total transaction of $3,739,118.40. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Corazon (Corsee) D. Sanders sold 2,665 shares of BeOne Medicines stock in a transaction dated Friday, September 5th. The stock was sold at an average price of $337.00, for a total value of $898,105.00. The SEC filing for this sale provides additional information. Insiders have sold 96,203 shares of company stock worth $30,923,233 over the last quarter. Corporate insiders own 6.62% of the company’s stock.

BeOne Medicines Stock Up 4.4%

Shares of NASDAQ ONC opened at $343.65 on Wednesday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.17 and a current ratio of 2.39. BeOne Medicines Ltd. – Sponsored ADR has a 1 year low of $170.99 and a 1 year high of $355.30. The stock’s 50-day simple moving average is $327.61 and its 200-day simple moving average is $289.50. The firm has a market cap of $37.68 billion, a price-to-earnings ratio of 673.82 and a beta of 0.31.

Analyst Ratings Changes

A number of research firms recently issued reports on ONC. Weiss Ratings reissued a “sell (d-)” rating on shares of BeOne Medicines in a research report on Wednesday, October 8th. Barclays assumed coverage on shares of BeOne Medicines in a research note on Thursday, September 18th. They set an “overweight” rating and a $385.00 price objective for the company. Citizens Jmp lifted their target price on shares of BeOne Medicines from $348.00 to $396.00 and gave the company a “market outperform” rating in a report on Friday, November 7th. Guggenheim upped their price target on shares of BeOne Medicines from $350.00 to $365.00 and gave the stock a “buy” rating in a research report on Thursday, August 7th. Finally, Royal Bank Of Canada increased their price target on BeOne Medicines from $374.00 to $395.00 and gave the company an “outperform” rating in a report on Friday, November 7th. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $357.33.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.